Computational Systems Analysis of Dopamine Metabolism

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2008 Jun 24

PMID 18568086

Citations 30

Authors

Zhen Qi

Gary W Miller

Eberhard O Voit

Affiliations

Soon will be listed here.

Abstract

A prominent feature of Parkinson's disease (PD) is the loss of dopamine in the striatum, and many therapeutic interventions for the disease are aimed at restoring dopamine signaling. Dopamine signaling includes the synthesis, storage, release, and recycling of dopamine in the presynaptic terminal and activation of pre- and post-synaptic receptors and various downstream signaling cascades. As an aid that might facilitate our understanding of dopamine dynamics in the pathogenesis and treatment in PD, we have begun to merge currently available information and expert knowledge regarding presynaptic dopamine homeostasis into a computational model, following the guidelines of biochemical systems theory. After subjecting our model to mathematical diagnosis and analysis, we made direct comparisons between model predictions and experimental observations and found that the model exhibited a high degree of predictive capacity with respect to genetic and pharmacological changes in gene expression or function. Our results suggest potential approaches to restoring the dopamine imbalance and the associated generation of oxidative stress. While the proposed model of dopamine metabolism is preliminary, future extensions and refinements may eventually serve as an in silico platform for prescreening potential therapeutics, identifying immediate side effects, screening for biomarkers, and assessing the impact of risk factors of the disease.

Citing Articles

Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC-H 106.

Lee H, Kim H, Choi D, Ko E, Choi J, Seo Y Pharmacol Res Perspect. 2023; 11(5):e01135.

PMID: 37740715 PMC: 10517640. DOI: 10.1002/prp2.1135.

Hallmarks of neurodegenerative disease: A systems pharmacology perspective.

Bloomingdale P, Karelina T, Ramakrishnan V, Bakshi S, Veronneau-Veilleux F, Moye M CPT Pharmacometrics Syst Pharmacol. 2022; 11(11):1399-1429.

PMID: 35894182 PMC: 9662204. DOI: 10.1002/psp4.12852.

A MOF-based carrier for dopamine delivery.

Pinna A, Ricco R, Migheli R, Rocchitta G, Serra P, Falcaro P RSC Adv. 2022; 8(45):25664-25672.

PMID: 35539814 PMC: 9082660. DOI: 10.1039/c8ra04969f.

DOPA Homeostasis by Dopamine: A Control-Theoretic View.

Kleppe R, Waheed Q, Ruoff P Int J Mol Sci. 2021; 22(23).

PMID: 34884667 PMC: 8657751. DOI: 10.3390/ijms222312862.

Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.

Nygaard G, Szigetvari P, Grindheim A, Ruoff P, Martinez A, Haavik J J Pers Med. 2021; 11(11).

PMID: 34834538 PMC: 8625014. DOI: 10.3390/jpm11111186.

References

Kim D, Szczypka M, Palmiter R . Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci. 2000; 20(12):4405-13. PMC: 6772455. View

Bennett M, Bishop J, Leng Y, Chock P, Chase T, Mouradian M . Degradation of alpha-synuclein by proteasome. J Biol Chem. 1999; 274(48):33855-8. DOI: 10.1074/jbc.274.48.33855. View

Takahashi N, Miner L, Sora I, Ujike H, Revay R, Kostic V . VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A. 1997; 94(18):9938-43. PMC: 23302. DOI: 10.1073/pnas.94.18.9938. View

Phillips J, Lam H, Ackerson L, Maidment N . Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur J Neurosci. 2006; 23(1):151-60. DOI: 10.1111/j.1460-9568.2005.04550.x. View

Carlsson A . The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959; 11(2, Part 2):490-3. View

Barbeau A . Dopamine and basal ganglia diseases. Arch Neurol. 1961; 4:97-102. DOI: 10.1001/archneur.1961.00450070099011. View

Savageau M . Biochemical systems analysis. 3. Dynamic solutions using a power-law approximation. J Theor Biol. 1970; 26(2):215-26. DOI: 10.1016/s0022-5193(70)80013-3. View

Mooslehner K, Chan P, Xu W, Liu L, Smadja C, Humby T . Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol Cell Biol. 2001; 21(16):5321-31. PMC: 87256. DOI: 10.1128/MCB.21.16.5321-5331.2001. View

Fumagalli F, Jones S, Bosse R, Jaber M, Giros B, Missale C . Inactivation of the dopamine transporter reveals essential roles of dopamine in the control of locomotion, psychostimulant response, and pituitary function. Adv Pharmacol. 1997; 42:179-82. DOI: 10.1016/s1054-3589(08)60722-x. View

10.

Huotari M, Gogos J, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A . Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci. 2002; 15(2):246-56. DOI: 10.1046/j.0953-816x.2001.01856.x. View

11.

Savageau M . Biochemical systems analysis. I. Some mathematical properties of the rate law for the component enzymatic reactions. J Theor Biol. 1969; 25(3):365-9. DOI: 10.1016/s0022-5193(69)80026-3. View

12.

Savageau M . Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. J Theor Biol. 1969; 25(3):370-9. DOI: 10.1016/s0022-5193(69)80027-5. View

13.

TYCE G, Dousa M, Muenter M . MAO and L-dopa treatment of Parkinson's disease. J Neural Transm Suppl. 1990; 29:233-9. DOI: 10.1007/978-3-7091-9050-0_22. View

14.

Doudet D, Chan G, Holden J, Pate B, Morrison K, Calne D . Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. Eur J Pharmacol. 1997; 334(1):31-8. DOI: 10.1016/s0014-2999(97)01157-6. View

15.

Kaur D, Peng J, Chinta S, Rajagopalan S, Di Monte D, Cherny R . Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging. 2006; 28(6):907-13. DOI: 10.1016/j.neurobiolaging.2006.04.003. View

16.

Schomburg I, Chang A, Hofmann O, Ebeling C, Ehrentreich F, Schomburg D . BRENDA: a resource for enzyme data and metabolic information. Trends Biochem Sci. 2002; 27(1):54-6. DOI: 10.1016/s0968-0004(01)02027-8. View

17.

Alvarez-Vasquez F, Sims K, Cowart L, Okamoto Y, Voit E, Hannun Y . Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae. Nature. 2005; 433(7024):425-30. DOI: 10.1038/nature03232. View

18.

Voit E, Almeida J . Decoupling dynamical systems for pathway identification from metabolic profiles. Bioinformatics. 2004; 20(11):1670-81. DOI: 10.1093/bioinformatics/bth140. View

19.

Leuner K, Muller W . The complexity of the dopaminergic synapses and their modulation by antipsychotics. Pharmacopsychiatry. 2006; 39 Suppl 1:S15-20. DOI: 10.1055/s-2006-931484. View

20.

Barbano P, Spivak M, Flajolet M, Nairn A, Greengard P, Greengard L . A mathematical tool for exploring the dynamics of biological networks. Proc Natl Acad Sci U S A. 2007; 104(49):19169-74. PMC: 2148263. DOI: 10.1073/pnas.0709955104. View